Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Clinical Advisors

Co-founder & Chair of Scientific Advisory Board
Sohail Tavazoie, M.D., Ph.D.

Dr. Sohail Tavazoie is the Leon Hess Professor, Howard Hughes Medical Institute Faculty Scholar and Head of the Meyer Laboratory of Systems Cancer Biology at The Rockefeller University.

Antoni Ribas, M.D., Ph.D.

Dr. Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles.

Tony Johnson, M.D.

Dr. Tony Johnson joined Goldfinch Bio as president and chief executive officer in 2017. He brings 25 years of academic, industry and venture experience including several years in R&D senior leadership roles.

Yelena Janjigian, M.D.

Dr. Yelena Y. Janjigian is a medical oncologist and Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Richard Carvajal, M.D.

Dr. Richard Carvajal is Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center.

Hossein Borghaei, D.O., M.S.

Dr. Borghaei is the Chief of Thoracic Medical Oncology and Professor, Department of Oncology/Hematology, Co-Director, Immune Monitoring Facility at Fox Chase Cancer Center in Philadelphia, PA.